Hizentra CIDP denied for missing prior authorization by Humana?

Humana's specific coverage criteria for hizentra cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Hizentra in CIDP

Humana requires prior authorization for Hizentra (subcutaneous immune globulin) in CIDP because immune globulin therapies involve significant cost and clinical complexity, and Humana uses the PA process to confirm that each member's documented clinical situation meets its coverage criteria before the claim is paid. A prior-auth denial means either that authorization was not obtained before the drug was dispensed, or that a submitted PA request was reviewed and denied on clinical grounds.

Understanding which situation applies is the first step. If the PA was denied on clinical grounds, that decision is a formal adverse benefit determination that triggers full internal and external appeal rights. If the PA was simply not submitted in time, your prescriber may be able to submit a retroactive request or an expedited request if the clinical situation is urgent.

## Federal Appeal Rights

• ACA §2719 / external review: A clinical denial of prior authorization is subject to independent external review after Humana's internal appeals are exhausted. The standard external-review window is approximately four months from the initial denial; the exact deadline is printed on your denial notice. Expedited external review (typically 72 hours) is available when standard review would endanger your health.
• ERISA §503: Self-funded employer plans must provide the specific PA criteria applied and a full-and-fair review opportunity.
• Medicare Advantage rules: If your coverage is through a Humana Medicare Advantage plan, CMS requires Humana to process standard PA decisions within defined timeframes and to provide a specific clinical rationale for any denial.

## What to Gather

1. Diagnosis confirmation — neurology notes, nerve conduction studies, or other objective testing establishing the CIDP diagnosis and current disease activity. 2. Functional status documentation — physician notes describing motor and sensory deficits and their impact on daily functioning. 3. Prior treatment history — a dated record of prior CIDP therapies tried (corticosteroids, IVIG, plasma exchange, or other treatments), with outcomes and reasons for transitioning to Hizentra. 4. Prescriber medical-necessity letter — a comprehensive letter from the treating neurologist explaining why Hizentra is the appropriate maintenance therapy, referencing applicable professional society guideline organizations (e.g., the American Academy of Neurology) without citing specific numeric thresholds. 5. Humana's PA criteria — obtain the current prior-authorization criteria for immune globulin/CIDP from Humana's provider portal or by written request; address each criterion explicitly.

## Criteria-Mapping Structure

| Humana PA Criterion | Chart or Prescriber Evidence Satisfying It | |---|---| | Each stated PA requirement | Exact date, note, test result, or prescriber attestation |